Generate Biomedicines, Inc. (GENB)
Price History
Mar 5, 2026 — Aug 31, 2026Investment Snapshot
- P/B of 4.31 — trading above book value
- Piotroski F-Score 0/9 — signs of financial weakness
- Loss-making — negative ROE of -48.9%
Generate Biomedicines, Inc. (GENB) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $2.0 billion . Key value metrics: P/B ratio 4.31, Piotroski F-Score 0 out of 9 .
Value Score
Key Metrics
Generate Biomedicines, Inc. — Fundamental Analysis Summary
On financial health, GENB shows a weak Piotroski F-Score of 0/9, a signal of deteriorating financial health, and negative return on equity of -48.9%.
StockPik's composite Value Score for GENB is 30/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.